drugset / Trial / NCT04067856
Intravitreal Dexamethasone Implant (Ozurdex) Versus Bevacizumab in Patients With Diabetic Macular Edema Undergoing Cataract Surgery
Withdrawn
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Allergan · collabDoheny Image Reading Center · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this research is to compare the effectiveness of bevacizumab (Avastin) with another a dexamethasone implant (Ozurdex), with respect to anatomic and visual outcomes as well as injection frequency in subjects undergoing cataract surgery with a concurrent diagnosis of diabetic macular edema (DME).
Timeline
- Start
- 2020-01-01
- Primary completion
- 2021-01-31
- Completion
- 2021-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 1.25 mg | Intravitreal |